Home » Loxo Oncology Secures Breakthrough Designation
Loxo Oncology Secures Breakthrough Designation
Loxo Oncology has scooped up a breakthrough therapy designation for its tropomyosin receptor kinase inhibitor candidate LOXO-101, the Stamford, Conn.-based company announced.
The drug candidate is designed to treat unresectable or metastatic solid tumors that have NTRK-fusion proteins in adult and pediatric patients with disease progression after treatment or those who don’t have other appropriate options.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May